You are here: Industry Insights > Lung cancer

News List

Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it? fiercepharma
June 05, 2018
Bristol-Myers Squibb’s new strategy In lung cancer relies on showing its new biomarker can help predict who benefits most from immunotherapy combinations.
AstraZeneca's Imfinzi survival win shores up the one lung cancer advantage it has fiercepharma
May 29, 2018
AstraZeneca’s Imfinzi already has an FDA approval in the lung cancer maintenance setting under its belt, something none of its rivals will be able to say for a while. And Friday, it hit another key benchmark to stretch out that lead.
Regeneron, Sanofi's drug shows positive effect in lung cancer study biospectrumasia
May 21, 2018
Regeneron's U.S. marketing application seeking approval for cemiplimab, a PD-1 inhibitor, for cutaneous squamous cell carcinoma is currently under FDA review with an action date of October 28.
Nivolumab reduces size of some lung cancer tumours, relapse rate after surgery europeanpharmaceuticalreview
April 17, 2018
A drug given to early-stage lung cancer patients before they undergo surgery showed major tumour responses in the removed tumour…
New data boosts Roche lung cancer combo pharmaphorum
March 30, 2018
Roche is hoping new data will help its cancer immunotherapy Tecentriq gain more traction, and prolong the shelf-life of its older cancer medicine Avastin.
Merck Receives Fast-Track Designation for Tepotinib in Non-Small Cell Lung Cancer in Japan biospace
March 28, 2018
Merck today announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved SAKIGAKE's rapid generic name for its researcher tepotinib*
Australian scientists to develop blood test for lung cancer biospectrumasia
March 12, 2018
The biomarker is expected to aid in predicting patients who would potentially respond to anti-PD-1 and anti-CTLA-4 immunotherapies.
NICE nods for AbbVie in hep C and Novartis in lung cancer pharmatimes
December 11, 2017
NICE has published new draft guidance for Novartis' Zykadia and AbbVie's Maviret.
Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemothera roche
December 08, 2017
First Phase III combination trial of a cancer immunotherapy to show improvement in progression-free survival as an initial treatment in advanced non-squamous non-small-cell lung cancer (NSCLC)
3 Top Drugmakers Leading Lung Cancer R&D Right Now biospace
November 21, 2017
Researchers are making great headway against cancer, even though it’s currently still the second-leading cause of death in the U.S.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page